Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs). Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.

FOAs Sponsored/Co-Sponsored by EGRP

NOTE: The following table lists the newest FOAs at the top of the table.

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
Research on Malignancies in the Context of HIV/AIDS
Summary Details
PAR-13-377External Web Site Policy (R01); see also PAR-13-378External Web Site Policy (R21) R01: Jan. 7, May 7, and Sept. 7
R21: Jan. 7, May 7, and Sept. 7
Sept. 8, 2016

Summary:
The purpose of these PAs is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). These PAs seek to encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both AIDS-defining and non-AIDS-defining malignancies in diverse populations.

These PAs invite research efforts that will: (1) provide information on the clinical outcomes of such cancers in the HIV-infected population; and (2) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Office of AIDS Malignancy Program, with the National Institute of Dental and Craniofacial Research (NIDCR). For more information: PAR-13-377External Web Site Policy (R01); PAR-13-378External Web Site Policy (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Methods and Technologies Branch, e-mail: starksv@mail.nih.gov

Mechanistic Insights from Birth Cohorts
Summary Details
PAR-13-109External Web Site Policy (R01); see also NOT-CA-13-002External Web Site Policy June 5, Oct. 5, 2013
Feb. 5, June 5, Oct. 5, 2014
Feb. 5, June 5, Oct. 5, 2015
Feb. 5, 2016
May 8, 2016

Summary:
This FOA is intended to support novel research on how prenatal exposures contribute to the etiology of chronic diseases and health conditions later in life. Little is known about the mechanisms by which such prenatal exposures lead to diabetes or obesity, renal, pulmonary, or cardiovascular or hematologic disease, neurodevelopmental disorders, reproductive health (i.e. fertility), or cancer. The goal of this FOA is to stimulate research by leveraging existing birth cohorts to address targeted mechanistic questions regarding the normal and abnormal developmental origins of organ systems and/or diseases of interest to the participating NIH Institutes and Centers. For more information: PAR-13-109External Web Site Policy and NOT-CA-13-002External Web Site Policy.

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Modifiable Risk Factors Branch; e-mail: mahabir@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-286External Web Site Policy (R01, R37) R01 and R37:
Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR encourages revision applications (formerly called "competing revisions") from currently funded R01s and R37s with at least one year left at the estimated time of award. Early-stage development is defined as the initial development or significant modification of existing tools for new applications. For more information: PAR-12-286External Web Site Policy (R01, R37)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Advanced Development of Informatics Technology
Summary Details
PAR-12-287External Web Site Policy (U24) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U24s for advanced development and enhancement of emerging informatics technologies, which are ones that have passed the initial prototyping and pilot development stage, demonstrated potential to have a significant and broader impact, have compelling reasons for further improvement and enhancement, and have not been widely adopted in the cancer research field. For more information: PAR-12-287External Web Site Policy (U24)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Early-Stage Development of Informatics Technology
Summary Details
PAR-12-288External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites U01s and focuses on early-stage development from prototyping to hardening and adaption. For more information: PAR-12-288External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-289External Web Site Policy (U01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR solicits revisions (formerly called "competing revisions") from currently funded U01s with at least one year left at the estimated time of award. For more information: PAR-12-289External Web Site Policy (U01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Revisions for Early-Stage Development of Informatics Technology
Summary Details
PAR-12-290External Web Site Policy (P01) Jan. 22, June 18, and Nov. 18, 2013
June 18 and Nov. 18, 2014
June 18, 2015
June 19, 2015

Summary:
This PAR invites revisions (formerly called "competing revisions") from currently funded P01s with at least one year left at the estimated time of award. For more information: PAR-12-290External Web Site Policy (P01)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Pilot Studies in Pancreatic Cancer
Summary Details
PA-11-298External Web Site Policy (R03)
PA-11-297External Web Site Policy (R21)
R03 and R21:
Feb. 16, June 16, and Oct. 16
Jan. 5, 2015

Summary:
These trans-NCI PAs are to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Inquiries about cancer control, epidemiology, and survivorship research proposals are handled by EGRP. For more information: PA-11-298External Web Site Policy (R03); PA-11-297External Web Site Policy (R21)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Small Grants Program for Cancer Epidemiology
Summary Details
PA-12-039External Web Site Policy (R03) Mar. 19, July 17, and Nov. 19, 2012
Mar. 19, July 23, and Nov. 19, 2013
Mar. 18, July 22, and Nov. 18, 2014
Nov. 19, 2014

Summary:
Most cancers are multi-factorial in etiology and require an understanding of how these factors modify and interact with each other in leading to cancer. This FOA provides support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology. Scientific emphasis in this FOA reflects high-priority areas in cancer epidemiology research which include methods and technologies, identification of modifiable risk factors, identification of host susceptibility factors, and clinical and translational epidemiology. For more information: PA-12-039External Web Site Policy (R03)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-11-250External Web Site Policy (R01) R01: Feb. 5, June 5, and Oct. 5 Sept. 8, 2014

Summary:
This PA invites multidisciplinary research applications that identify, examine, and address the ethical, legal, and social implications (ELSI) of advances in genomic research and technology for individuals, families, communities, and society more broadly. NCI is interested in empirical research that focuses on the ethical, legal, and social issues related to heritable cancer syndromes. Study of the psychosocial and behavioral impact on affected individuals, their families, and populations and research that takes into consideration the perpsectives of diverse racial, ethnic, and socioeconomic backgrounds, as well as children, older adults, and people with disabilities, is highly desirable. The ultimate goal of this research will be to improve outcomes related to the diagnosis of heritable cancer syndromes. The National Human Genome Research Institute (NHGRI) is the lead sponsor of the PA; several other NIH Institutes also are cosponsors. For more information: PA-11-250External Web Site Policy (R01).

Contact: Charlisse Caga-anan, J.D., Program Director, Host Susceptibility Factors Branch, e-mail: cagaananef@mail.nih.gov

Analysis of Genome-Wide Gene-Environment (GxE) Interactions
Summary Details
PAR-13-382External Web Site Policy (R21) Feb. 14, 2014 Feb. 15, 2014

Summary:
This FOA is intended to support novel research projects that involve secondary data analyses of existing genome-wide data from genome-wide association studies or other large genomic datasets for the purpose of identifying gene-environment interactions. The ultimate objective of this funding opportunity is the discovery of complex interplays of genes and environmental factors in human populations which may reveal novel genetic susceptibilities to environmental exposures or a greater understanding of the role of environmental exposures in the development, progression, and severity of complex human diseases.

NCI encourages applications that contain novel statistical methods, computational and analytical tools, and designs for studying interactions of genetic and environmental factors for studies of cancer etiology and prognosis. Applications may include statistical methods for large-scale gene-environment analysis of disease pathways for cancer risk assessment, early detection, prevention, and outcome. NCI is also interested in studies of gene-environment which incorporate early cancer biomarkers. For more information: PAR-13-382External Web Site Policy (R21)

Contact: Leah Mechanic, Ph.D., M.P.H., Program Director, Host Susceptibility Factors Branch, e-mail: mechanil@mail.nih.gov

Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis
Summary Details
PA-11-073External Web Site Policy (R01)
PA-11-074External Web Site Policy (R21)
R01: Feb. 5, June 5, and Oct. 5
R21: Feb. 16, June 16, and Oct. 16
Jan. 8, 2014

Summary:
These PAs are intended to stimulate the development and validation of novel mitochondrial (mt) DNA biomarkers for understanding the etiology, early detection, diagnosis, prognosis, and risk assessment of cancer; and responses to preventive and ameliorative treatment. These PAs are cosponsored with NCI's Division of Cancer Prevention (DCP), Division of Cancer Treatment and Diagnosis (DCTD), and the Office of the Director (OD). For more information: PA-11-073External Web Site Policy (R01); PA-11-074External Web Site Policy (R21)

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology
Summary Details
PAR-14-160External Web Site Policy (U01) July 8 and Nov. 10, 2014
Mar. 11, July 8, and Nov. 10, 2015
Mar. 11, July 8, and Nov. 10, 2016
Mar. 10, 2017
Mar. 11, 2017

Summary:
This PAR invites grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This PAR will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genomics Research Program (EGRP) and other components of NCI’s Division of Cancer Control and Population Sciences (DCCPS). For more information: PAR-14-160External Web Site Policy (U01) and FAQs

Contact: Daniela Seminara, Ph.D., M.P.H, Scientific Consortia Coordinator and Program Director, Office of the Associate Director e-mail: seminara@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP


Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations. View current and past issues and subscribe.

Return to Top